AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Report Publication Announcement Feb 26, 2018

4959_10-k_2018-02-26_9dc90a33-ba90-47d7-aa26-2fb11553c457.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8359F

ConvaTec Group PLC

26 February 2018

2017 Annual Report & Accounts

READING, UNITED KINGDOM (26 February 2018) - ConvaTec Group Plc ("ConvaTec" or the "Group"), a leading global medical products and technologies company, has today published on the Group's website its Annual Report & Accounts for the year ended 31 December 2017 (the "Annual Report").  The Annual Report is available at www.convatecgroup.com.

In compliance with Listing Rule 9.6.1, a copy of the Annual Report will also shortly be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/NSM.

The Annual Report, together with notice of the Group's Annual General Meeting to be held on 10 May 2018, will be sent to shareholders later this month, at which point a further announcement will be made.

Enquiries

Media

Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                             +44 (0)207 251 3801

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582

[email protected]

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSKMGZZKFGGRZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.